Security key
03836J201
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)
CUSIP: 03836J201
Q4 2023 13F Holders as of 31 Dec 2023
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Shares outstanding
- 9,144,889
- Total 13F shares
- 926,780
- Share change
- +5,662
- Total reported value
- $4,355,977
- Price per share
- $4.70
- Number of holders
- 19
- Value change
- +$26,645
- Number of buys
- 5
- Number of sells
- 5
Report period
Q4 2023
Institutions
19
Top holders
10
APRE full security history
Newer quarter: Q1 2024
Previous quarter: Q3 2023
Aprea Therapeutics, Inc. SEC filings
Aprea Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03836J201
Recent filing periods:
Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| AIGH Capital Management LLC |
13F
|
Company |
3.8%
|
349,300
|
$1,457,407 | — | 30 Sep 2023 | |
| Sio Capital Management, LLC |
13F
|
Company |
3.1%
|
280,000
|
$1,166,620 | — | 30 Sep 2023 | |
| Worth Venture Partners, LLC |
13F
|
Company |
0.95%
|
87,169
|
$365,238 | — | 30 Sep 2023 | |
| Walleye Capital LLC |
13F
|
Company |
0.9%
|
82,356
|
$345,072 | — | 30 Sep 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.3%
|
27,341
|
$113,916 | — | 30 Sep 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
17,473
|
$73,238 | — | 30 Sep 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.16%
|
14,562
|
$60,672 | — | 30 Sep 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.1%
|
9,230
|
$38,457 | — | 30 Sep 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.04%
|
3,250
|
$13,540 | — | 30 Sep 2023 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
2,160
|
$9,050 | — | 30 Sep 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
1,747
|
$7,280 | — | 30 Sep 2023 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.01%
|
1,000
|
$4,167 | — | 30 Sep 2023 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0.01%
|
806
|
$3,358 | — | 30 Sep 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
317
|
$1,000 | — | 30 Sep 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
270
|
$1,125 | — | 30 Sep 2023 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
200
|
$833 | — | 30 Sep 2023 | |
| Bull Oak Capital, LLC |
13F
|
Company |
0%
|
39
|
$162 | — | 30 Sep 2023 | |
| Creative Planning |
13F
|
Company |
0%
|
25
|
$105 | — | 30 Sep 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
4
|
$17 | — | 30 Sep 2023 | |
| Princeton Global Asset Management LLC |
13F
|
Company |
0%
|
100
|
$417 | — | 30 Sep 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
3
|
$13 | — | 30 Sep 2023 | |
| Christian S. Schade |
3/4/5
|
Director |
—
mixed-class rows
|
312,846
mixed-class rows
|
$976,345 | — | 28 Jul 2022 | |
| Scott M. Coiante |
3/4/5
|
SVP, Chief Financial Officer |
—
mixed-class rows
|
234,265
mixed-class rows
|
$533,970 | — | 28 Jul 2022 | |
| Eyal C. Attar |
3/4/5
|
SVP, Chief Medical Officer, Director |
—
class O/S missing
|
57,392
|
$211,254 | — | 03 Jun 2022 | |
| Gregory Alan Korbel |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
81,462
mixed-class rows
|
$168,445 | — | 28 Jul 2022 | |
| Lars B. Abrahmsen |
3/4/5
|
SVP, Chief Scientific Officer |
—
mixed-class rows
|
143,700
mixed-class rows
|
$160,855 | — | 10 Mar 2022 | |
| Fouad Namouni |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 | |
| Michael Aaron Kelly |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 |
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q4 2023
As of 31 Dec 2023,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
926,780 shares.
The largest 10 holders included
AIGH Capital Management LLC, Sio Capital Management, LLC, Worth Venture Partners, LLC, Walleye Capital LLC, ROYAL BANK OF CANADA, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, BlackRock Inc., and BANK OF AMERICA CORP /DE/.
This page lists
19
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
19
Q4 2023 holders
19
Holder diff
0
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 Value $ | Q4 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.